TALEN/CRISPR-mediated engineering of a promoterless anti-viral RNAi hairpin into an endogenous miRNA locus by Senís, Elena et al.
Published online 9 September 2016 Nucleic Acids Research, 2017, Vol. 45, No. 1 e3
doi: 10.1093/nar/gkw805
TALEN/CRISPR-mediated engineering of a
promoterless anti-viral RNAi hairpin into an
endogenous miRNA locus
Elena Senı́s1,2, Stefan Mockenhaupt1,2, Daniel Rupp3,4, Tobias Bauer5,
Nagarajan Paramasivam5,6, Bettina Knapp7, Jan Gronych8, Stefanie Grosse1,2, Marc
P. Windisch3, Florian Schmidt1,2, Fabian J. Theis7,9, Roland Eils2,5,10, Peter Lichter8,
Matthias Schlesner5, Ralf Bartenschlager3,4 and Dirk Grimm1,2,*
1Department of Infectious Diseases, Virology, Heidelberg University Hospital, Cluster of Excellence CellNetworks,
Heidelberg, 69120, Germany, 2BioQuant Center, University of Heidelberg, Heidelberg, 69120, Germany,
3Department of Infectious Diseases, Molecular Virology, Heidelberg University Hospital, Heidelberg, 69120,
Germany, 4Division of Virus-Associated Carcinogenesis (F170), German Cancer Research Center (DKFZ),
Heidelberg, 69120, Germany, 5Division of Theoretical Bioinformatics (B080), German Cancer Research Center
(DKFZ), Heidelberg, 69120, Germany, 6Medical Faculty Heidelberg, Heidelberg University, Heidelberg, 69120,
Germany, 7Institute of Computational Biology, Helmholtz Zentrum München, Neuherberg, 85764, Germany, 8Division
of Molecular Genetics (B060), German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK),
Heidelberg, 69120, Germany, 9Department of Mathematics, Technische Universität München, Garching, 85748,
Germany and 10Department for Bioinformatics and Functional Genomics, Institute for Pharmacy and Molecular
Biotechnology (IPMB), Heidelberg University, Heidelberg, 69120, Germany
Received March 24, 2016; Revised August 31, 2016; Accepted September 04, 2016
ABSTRACT
Successful RNAi applications depend on strategies
allowing robust and persistent expression of mini-
mal gene silencing triggers without perturbing en-
dogenous gene expression. Here, we propose a
novel avenue which is integration of a promoter-
less shmiRNA, i.e. a shRNA embedded in a micro-
RNA (miRNA) scaffold, into an engineered genomic
miRNA locus. For proof-of-concept, we used TALE or
CRISPR/Cas9 nucleases to site-specifically integrate
an anti-hepatitis C virus (HCV) shmiRNA into the
liver-specific miR-122/hcr locus in hepatoma cells,
with the aim to obtain cellular clones that are ge-
netically protected against HCV infection. Using re-
porter assays, Northern blotting and qRT-PCR, we
confirmed anti-HCV shmiRNA expression as well as
miR-122 integrity and functionality in selected cel-
lular progeny. Moreover, we employed a compre-
hensive battery of PCR, cDNA/miRNA profiling and
whole genome sequencing analyses to validate tar-
geted integration of a single shmiRNA molecule at
the expected position, and to rule out deleterious ef-
fects on the genomes or transcriptomes of the en-
gineered cells. Importantly, a subgenomic HCV repli-
con and a full-length reporter virus, but not a Dengue
virus control, were significantly impaired in the mod-
ified cells. Our original combination of DNA engi-
neering and RNAi expression technologies benefits
numerous applications, from miRNA, genome and
transgenesis research, to human gene therapy.
INTRODUCTION
Originally discovered in plants and worms, RNA interfer-
ence (RNAi) has become a powerful and versatile technol-
ogy for gene regulation in biology and medicine (1,2). A ma-
jor part of its popularity is due to the ease with which it is
triggered in mammalian cells, as it merely requires the de-
livery of double-stranded RNA mimics of endogenous mi-
croRNAs (miRNAs), such as short hairpin RNAs, which
engage the intrinsic cellular RNAi machinery for process-
ing and target mRNA inhibition. Particularly appealing is
that artificial RNAi triggers can be expressed from vari-
ous promoters and encoded by non-viral or viral gene de-
livery vectors, yielding a comprehensive toolbox for appli-
cations ranging from fundamental gene annotation in cul-
tured cells, to therapeutic (m)RNA suppression in humans.
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Very attractive clinical targets are viral pathogens such as
the hepatitis B or C viruses (HBV or HCV, respectively)
since they go through an obligatory RNA phase that is vul-
nerable to RNAi (3,4), and since many established treat-
ments have limited efficacy and/or adverse side effects. In-
deed, we and others have previously exemplified the tremen-
dous potential of RNAi for robust and stable in vivo sup-
pression of hepatitis viruses, including in HBV-transgenic
mice that were infused with liver-specific Adeno-associated
viral vectors of type 8 (AAV8) encoding anti-HBV shRNAs
(5–9).
Still, RNAi applications and their clinical translation re-
main severely hampered by concerns over specificity, safety
and longevity (Figure 1A). Particularly alarming are find-
ings in different animal species, from mice to primates, that
shRNA over-expression from strong RNA polymerase III
promoters can cause cytotoxicity, organ failure and lethal-
ity (8,10–13). Possible reasons include adverse off-targeting
and dose-dependent saturation of the cellular RNAi ma-
chinery which is needed for processing and functionality
of miRNAs and other endogenous RNAi triggers. This has
tempted us and others to improve RNAi expression strate-
gies, for instance by pre-selecting inherently safe and potent
shRNAs (8,14), or by placing shRNAs under weak and/or
tissue-specific promoters (7). Another strategy to diminish
in vivo RNAi toxicity is to embed an ectopic RNAi sequence
within a cellular miRNA, by replacing one of the two arms
of the double-stranded miRNA with the shRNA antisense
arm, resulting in a so-called shmiRNA (15–19).
While all these avenues can mitigate adverse RNAi effects
to some extent, a major remaining challenge is to combine
these advances with equally improved strategies for safe and
specific ex or in vivo RNAi delivery. A promising option are
vectors derived from AAV as they are non-pathogenic, easy-
to-engineer and retargetable to tissues and cells of choice
(20–24). However, because their genomes remain predom-
inantly episomal and are rapidly lost in dividing cells (25)
(Figure 1A), the usefulness of AAV/RNAi vectors is highest
in quiescent tissues, such as the liver, or in applications re-
quiring short-term RNAi expression. Conversely, integrat-
ing vectors derived from retro- or lentiviruses permit long-
term RNAi expression, but due to their promiscuity bear
a risk of insertional mutagenesis and progression to clonal
expansion or oncogenesis (26–29). Mechanisms include dis-
ruption of tumor suppressor genes, or activation of neigh-
boring oncogenes by vector-borne promoter/enhancer ele-
ments. The latter was observed in retro- or lentiviral gene
therapy trials, and it was also noted in mice that developed
hepatocellular carcinoma due to AAV vector integration
into a certain locus (Rian) and activation of proximal small
RNAs and genes (30–32). Additional concerns about im-
precise vector integration include insufficient control over
the number of insertion events and over local effects from
the integration site, and consequently limited options to
govern RNAi expression levels. Finally, ectopic promoters
can vary in their strength between different cell types or
become silenced over time, further complicating the fine-
tuning of sh(mi)RNA expression levels and the establish-
ment of lifelong RNAi phenotypes, even in non-dividing
cells (33–35).
Here, we developed and validated a novel RNAi expres-
sion strategy that alleviates these vector-associated con-
cerns and uncertainties, and that concurrently exploits the
benefit of higher safety of miRNA-embedded shmiRNAs.
To this end, we devised the original concept to stably in-
tegrate a minimal promoterless shmiRNA hairpin into an
endogenous miRNA locus, in order to hijack the cellu-
lar miRNA promoter for long-term shmiRNA expression
at robust yet non-toxic levels (Figure 1B). For proof-of-
principle and convenient read-out, we harnessed TALE
and CRISPR/Cas9 nucleases to insert a shmiRNA against
HCV, a human pathogen that is susceptible to RNAi
(36,37), into the genomic miR-122 locus (hcr) .The latter
is abundantly and specifically expressed in liver cells, where
HCV infection occurs (38). Using a comprehensive battery
of assays including whole genome sequencing, we show that
it is indeed possible to obtain engineered cellular clones that
still largely resemble the parental cells, but that are stably
protected against HCV replication and infection. As the
identical strategy can likely be customized for many further
miRNA loci and for any RNAi target, we expect the new
concept introduced here to hold significant potential for a
wide scope of basic or therapeutic RNAi applications.
MATERIALS AND METHODS
Details on plasmids, vectors, cell culture, transfections,
PCRs, Northern blotting, luciferase assays, FISH and sta-
tistical analysis are found in Supplementary Methods.
Generation of stable shmiRNA cell lines
Huh7 cells were transfected as described in Supplementary
Methods with TALEN or CRISPR/Cas9 expression plas-
mids together with the homologous recombination tem-
plate pSSV9-hcr-donor-shmiRHCV318. Fourty-eight to 72
h post-transfection, cells were trypsinized and transferred
to 15 cm dishes. They were then cultured for at least 15 days
in Huh7 media supplemented with 500 g/ml G418, before
single colonies were picked and transferred to 96-well plates.
Genomic DNA was extracted from these colonies using Di-
rectPCR Lysis Reagent Cell (PeqLab, Erlangen, Germany)
and analyzed by polymerase chain reaction (PCR) to as-
sess the occurrence of proper homologous recombination.
Positive colonies were expanded and eventually re-seeded in
24-well plates. Two wells of each cell line were transduced
with an AAV vector expressing Cre recombinase, while a
third well was treated with an AAV vector expressing YFP
as a transduction control (see next chapter for details). Two
days after transduction, genomic DNA was extracted from
the cells of one of the Cre-treated wells and analyzed by
PCR, to monitor the formation of minicircle DNA derived
from Cre-mediated excision of the floxed NeoR cassette. The
cells from the other well were trypsinized and transferred
to 15 cm dishes to allow formation of single colonies for
subcloning. The cells were then cultured for approximately
seven days in Huh7 media without G418 (and diluted again,
in case the initial cell density turned out to be too high for
colony formation from a single cell). Afterward, colonies
were again picked and analyzed by PCR to validate that the
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Figure 1. Comparison of (A) conventional and (B) novel RNAi expression strategies. (A) Traditional delivery of exogenous RNAi sequences in the form
of shRNAs (orange) or miRNA-embedded RNAi hairpins (shmiRNAs, green). Both strategies require an exogenous promoter (red arrow) for expression
of the ectopic RNAi molecule. Depending on the strength of this promoter and on inherent features of the shRNA, this can result in adverse accumulation
of RNAi triggers in the cell and ensuing cytotoxicity. Alternatively, cells will lose episomal shRNA or shmiRNA cassettes due to dilution during cell
division. One solution (not depicted) can be stable integration using, e.g. retro- or lentiviruses, but this may cause insertional mutagenesis and oncogenesis.
Moreover, insufficient control over the insertion events diminishes the options to govern RNAi expression levels. (B) In the new strategy introduced here, a
minimal promoterless shmiRNA hairpin (green) is integrated into a cellular miRNA gene (blue), to be expressed from the cognate endogenous promoter
at non-toxic levels. Co-integration of a selection marker (not shown) permits removal of cells that have failed to incorporate the RNAi hairpin, in turn
resulting in a population of cells that stably and robustly express the shmiRNA.
PCR product was sub-cloned and sequenced, and positive
clones were characterized further.
To generate the stable HEK293 cells used in Supplemen-
tary Figure S9, no colonies were picked after treatment with
the Cre-expressing AAV vector. Instead, based on the 100%
efficiency of the AAV/Cre vector, the entire cell pool was
used for further analysis.
AAV transductions
To eliminate the floxed NeoR cassette from the shmiRNA-
engineered clones, they were transduced with AAV vectors
expressing Cre recombinase. To this end, the different Huh7
or HEK293 clones were seeded at 5 × 104 cells per well in
24-well plates and 24 h later transduced with AAV vectors,
expressing either Cre recombinase or a YFP control, at a
multiplicity of infection (MOI) of 4 × 104 viral genomes per
cell. Cells were re-seeded for colony picking (Huh7) or for
luciferase assays (HEK293), or harvested for PCR analysis
48 h post-transduction.
Whole genome sequencing analysis
Whole genome sequencing was performed on Huh7 T2 31.3
and Huh7 wildtype (WT) cells to validate the specificity
of shmiRHCV318 integration and to identify possible off-
target integration sites. After library preparation, sequenc-
ing was performed using the Illumina HiSeq platform.
Sequencing reads were aligned against the human refer-
ence genome hs37d5 (http://www.1000genomes.org/home)
and the shmiRHCV318 as separate contig using the BWA-
MEM (v0.7.8) software (39). Resulting BAM files were
coordinate-sorted, merged and PCR duplicates marked by
biobambam (v0.0.148) software (40). The resulting BAM
files have an average coverage of 19.82x and 21.69x for
WT and T2 31.3 cells, respectively (0x and 12.69x on the
shmiRHCV318 contig). The integration site at chr18 and
the shmiRHCV318 contig were visualized by using IGV
(41).
Gene and miRNA expression profiling
Prior to using total RNA samples for gene and miRNA ex-
pression profiling, their quality was assessed via two meth-
ods. First, RNA concentration as well as A260/280 and
A260/230 ratios were measured using a Nanovue Plus Spec-
trophotometer (GE Healthcare, Pasching, Austria). Sec-
ond, the RNA integrity number (RIN) was determined us-
ing the Agilent 2100 Bioanalyzer and the Agilent RNA 6000
Nano Kit (both Agilent Technologies, Waldbronn, Ger-
many) following the manufacturer’s instructions. Samples
with a high RNA quality (RIN near or equal to 10) were
then subjected to gene and miRNA expression profiling at
the German Cancer Research Center (DKFZ, Heidelberg,
Germany), Genomics and Proteomics Core Facility. Three
biological replicates (different cell passages) were provided
for each cell clone.
Gene expression profiling was performed using
Affymetrix Human Genome U133 Plus 2.0 arrays.
Raw expression values were quantile-normalized and
log2-transformed. A principal component analysis showed
a cumulative R2 of 0.99 within the first two principal
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of each sample (T2 31.3, TS 30.20 and U6 20.16) as
compared to the WT samples and pairwise between the
samples (after correction for the WT) were computed,
and a fixed-effects linear model was fit for each individual
gene to estimate expression differences. An empirical
Bayes approach was used to moderate the standard errors
of the normalized log2 fold-changes. Finally, we used a
two-sided moderated t-test to compute P-values controlled
by Benjamini–Hochberg for multiple testing. Genes with
an absolute log2 fold-change larger than 1 and a corrected
P-value < alpha = 0.05 were assigned to be differentially
expressed with high significance.
MiRNA expression profiling was performed using the
Agilent-046064 Unrestricted Human miRNA V19.0 Mic
roarray. Raw miRNA microarray data were pre-processed
with background subtraction using the ‘normexp’ convo-
lution standard method with subsequent quantile normal-
ization as implemented in the Bioconductor limma pack-
age (v3.22.1) (42) for R statistical software (v3.1.2). Expres-
sion values were log2-transformed, and probe duplicates
were averaged and quantile normalized to ensure compa-
rability between samples. Potential batch effects between
Agilent chips conducted at different dates were reduced
by the ComBat-function in the Bioconductor sva-package
(v3.12.0) on the basis of an empirical Bayesian framework
(43).
We calculated differential gene expression on quantile-
normalized Affymetrix mRNA expression profiles with the
R statistical software (44) (v3.1.0). Data were filtered for
low expression and variance with standard parameters, re-
taining 12 680 (of 54 675) probe IDs. Significance Analy-
sis of Microarrays ((45), R-package ‘siggenes’ v1.40.0 (46))
was performed and differentially expressed probe IDs were
called at a false discovery rate threshold of <0.05. The same
procedure was applied to the Agilent microarray data to
identify differentially expressed miRNAs.
HCV inhibition experiments
In vitro transcription of plasmids pFKi341PiLucNS3-
3′-JFH1-dg, pFKi341PiLucNS3-3′-JFH1-dg-dGDD,
pFKi389-JCR2a-dg-JC1 and pFKi389-JCR2a-dGDD-
dg-JC1 (all 10 g, MluI-linearized) was used to generate
subgenomic or full-length HCV RNA, respectively. Like-
wise, in vitro transcription of 10 g of XbaI-linearized
plasmid pFK-sgDVs-R2A (47) resulted in subgenomic
Dengue virus replicon RNA. DNA was purified by using
the NucleoSpin Gel and PCR Clean up Kit (Macherey
Nagel, Düren, Germany) according to the manufacturer’s
instructions. In vitro transcription reaction mixtures (total
volume 100 l) for use with T7 polymerase contained 80
mM HEPES (pH 7.5), 12 mM MgCl2, 2 mM spermidine,
40 mM dithiothreitol (DTT), 3.125 mM of each nucleoside
triphosphate, 1 U/l RNasin (Promega), 0.1 g/l of plas-
mid DNA and 0.6 U/l of T7 RNA polymerase (Promega).
For HCV transcripts and use with SP6 polymerase, the mix
contained 80 mM HEPES (pH 7.5), 16 mM MgCl2, 2 mM
spermidine, 40 mM DTT, 3.125 mM each of rATP, rCTP
and rUTP, 1.5625 mM of rGTP, 1 mM m7G(5′)ppp(5′)G
RNA cap structure analog, 1 U/l of RNasin, 0.1 g/l
of plasmid DNA and 0.6 U/l of SP6 RNA polymerase
(Promega). After a 2 h incubation at 37◦C (HCV) or 40◦C
(Dengue virus), 0.3 U of T7 RNA polymerase or 0.4 U of
SP6 RNA polymerase, respectively, were added per l of
reaction mixture, and the reaction mixture was incubated
overnight. Transcription was terminated by adding 1.2 U
of RNase-free DNase (Promega) per g plasmid DNA and
30 min incubation at 37◦C. RNA was extracted with acidic
phenol and chloroform, precipitated with isopropanol at
room temperature and dissolved in RNase-free water.
For electroporations, single-cell suspensions of WT or
engineered Huh7 clones were prepared by trypsinization,
washing with 1x phosphate buffered saline (PBS) and re-
suspension at a concentration of 1 × 107 cells per ml in
Cytomix (48) supplemented with 2 mM adenosine triphos-
phate (ATP) and 5 mM glutathione. Next, 2.5 g in vitro
transcripts were mixed with 100 l cell suspension and
transfected by electroporation using a GenePulser system
(Bio-Rad, Hercules, CA, USA) and a 0.2 cm gap cuvette
(Bio-Rad) at 500 F and 166 V. Cells were diluted immedi-
ately in complete Dulbecco’s modified Eagle’s medium and
seeded.
JCR2a virus was produced in Huh7.5 cells by electropo-
ration of HCV RNA. Supernatants were harvested every 24
h between 48 and 96 h after electroporation. Infectious titer
(median tissue culture infective dose, TCID50) was deter-
mined by limited dilution. For infection, Huh7 cells were
seeded at 5 × 104 cells per well in a 24-well plate 1 day prior
to infection with a MOI of 0.5.
For luciferase assays, cells were lysed in luciferase lysis
buffer (1% [v/v] Triton X-100, 10% [v/v] glycerol, 25 mM
glycyl-glycine pH 7.8, 15 mM l MgSO4, 4 mM EGTA,
kept at 4◦C and freshly supplied with 1 mM DTT imme-
diately before use). For luciferase measurements, cells were
washed once with PBS, lysed directly in the 96-well plate
with 30 l lysis buffer per well and frozen at −80◦C. Shortly
before measurement, lysates were allowed to thaw at room
temperature for 30 to 60 min. Firefly luciferase activity was
measured for 3 s in a Mithras LB940 multimode microplate
reader (Berthold Technologies, Bad Wildbad, Germany).
Renilla luciferase activity was measured for 10 s. Firefly as-
say buffer (25 mM glycyl-glycine pH 7.8, 15 mM K2PO4
pH 7.8, 15 mM MgSO4, 4 mM EGTA, 1 mM DTT, 2 mM
ATP) supplemented with 70 M D-luciferin (PJK GmbH,
Kleinblittersdorf, Germany), or Renilla assay buffer (25
mM glycyl-glycine pH 7.8, 15 mM K2PO4 pH 7.8, 15 mM
MgSO4, 4 mM EGTA, 1 mM DTT) supplemented with 1.5
M Coelenterazine (PJK GmbH), was added to each well
automatically prior to each measurement.
Data access
All microarray data are available in the NCBI Gene Expres-
sion Omnibus database (GEO; http://www.ncbi.nlm.nih.
gov/geo/) under accession number GSE68638. The whole
genome sequencing data have been deposited in the Euro-
pean Genome-phenome Archive (EGA, https://www.ebi.ac.
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RESULTS
Design and validation of an anti-HCV shmiRNA for integra-
tion into the hcr locus
To create an effective anti-HCV shmiRNA, we harnessed
the antisense sequence of the published HCV-specific
shRNA HCV-321 (36) that binds a highly conserved tar-
get in the HCV 5′NTR (non-translated region) starting at
nucleotide 321. For adaptation to the precursor of human
miR-122 (used as scaffold for our shmiRNA design), we
added three nucleotides to the 3′ end of the shRNA, yielding
an extended 22 nucleotides long antisense sequence starting
at HCV position 318 (accordingly named shmiRHCV318,
Figure 2A). Importantly, we have recently validated anti-
HCV efficacy of an analogous shRNA (shHCV318), prov-
ing that this part of the HCV genome is well accessible (49).
While considering a suitable integration site within the
miR-122 locus (hcr), we realized that the precursor (pre-
)miR-122 hairpin is located close to the putative hcr
polyadenylation signal (Supplementary Figure S1A). It
thus appeared reasonable to integrate the shmiRNA up-
stream of the miR-122 hairpin, to ensure its proper inclu-
sion into the full transcript. We moreover argued that tar-
geting a site inherently lacking a local RNA structure would
increase the likelihood of preserving folding and processing
of the miR-122 stem-loop. We therefore computationally
predicted the RNA secondary structure of the hcr 3′ end
including the precursor (pre-)miR-122 hairpin, and then
selected one exposed site 63 nt upstream of pre-miR-122
(or 76 nt upstream of the miR-122 5p arm, respectively)
for shmiRNA integration (Supplementary Figures S1B and
S2).
To verify that this position permits miR-122 and
shmiRNA co-expression, we generated plasmids expressing
1.2 kb of the hcr gene (hg38: chr18: 58450012–58451248)
comprising miR-122 alone or co-encoding shmiRHCV318
(manually cloned into position hg38: chr18: 58451012).
Two further constructs contained a shmiRNA against a
different target (human alpha-1-antitrypsin, hAAT), either
in place of shmiRHCV318 or in combination, the lat-
ter resulting in a triple hairpin (Figure 2B). These con-
structs served as control for the anti-HCV shmiRNA, and
to assess whether our strategy would enable multiplex-
ing of three hairpins. Co-transfections of HEK293T cells
(human embryonic kidney cells lacking miR-122 expres-
sion) with these expression plasmids and luciferase re-
porters carrying perfect binding sites for the different hair-
pins confirmed that each shmiRNA potently and specif-
ically inhibited its cognate target (Figure 2C). Notably,
this was observed for both configurations, double (either
shmiRHCV318 or shmiRhAAT plus miR-122) and triple
hairpins (shmiRHCV318, shmiRhAAT and miR-122). Ac-
tivity of the co-encoded miR-122 hairpin was comparably
high in all four plasmids, and only marginally and non-
significantly reduced in the triple versus the single miR-122
expression plasmid (Figure 2C, blue bars; best visible in the
right graph). Collectively, this demonstrates the feasibility
to co-express at least two exogenous shmiRNAs together
with miR-122 without significantly compromising its func-
tion.
Efficient and specific anti-HCV shmiRNA integration into
the miR-122 locus via homologous recombination
To site-specifically and efficiently integrate shmiRHCV318
into the hcr locus of liver cells, we devised a homolo-
gous recombination strategy based on potent TALEN and
CRISPR constructs against human miR-122 from our lab
(50) (Supplementary Figure S3 and Figure 3A). We chose
the human hepatocarcinoma cell line Huh7 as target since
it is susceptible to HCV infection and abundantly expresses
miR-122 (38). Notably, despite being a tumor-derived cell
line, Huh7 carries only two copies of the long arm of chro-
mosome 18 where the hcr/miR-122 locus resides, as demon-
strated by multiplex fluorescence-in-situ-hybridization (M-
FISH) (Supplementary Figure S4). The recombination tem-
plate contained the shmiRHCV318 hairpin plus a floxed
neomycin resistance (NeoR) cassette for selection, flanked
on each side by 1.25 kb of DNA homologous to the
hcr locus (the 3′ homology arm comprised the miR-122
hairpin). Following nuclease and template co-transfection
and G418 selection, single colonies were picked and an-
alyzed by PCR, to detect and distinguish random ver-
sus directed shmiRHCV318 integration. Results from the
TALEN-based approaches are shown in Figure 3B (for
primer sequences see Supplementary Table S1), illustrating
that roughly 90% of all clones that were negative for random
integration showed proper insertion of the exogenous hair-
pin into the hcr locus. If we factor in that we pre-selected
for, and excluded, negative clones (random integration), we
still calculate around 65% positive clones (correct insertion)
for the best TALEN pair T2 (Figure 3C).
Curiously, in our first experiments, the efficiencies of ho-
mologous integration were substantially lower with the TS
TALEN pair as well as the CRISPR strategy, reaching only
up to 7.1% or 3.3%, respectively (Figure 3B and C, and data
not shown). We then realized that both, the TS TALEN
pair and the anti-miR-122 gRNA, bind and inadvertently
cleave a sequence that partially overlaps with the miR-122
hairpin and is thus fully conserved in the shmiRHCV318-
containing repair template (see also Supplementary Fig-
ure S3), providing a likely explanation for their inferior
performance. In line with this, the much more effective
TALEN pairs T1 and T2 exclusively recognize and cleave
the endogenous hcr locus, but not the repair DNA. For
the gRNA-based strategy, a possible solution was to mu-
tate the protospacer-adjacent motif (PAM, a critical three
nucleotide sequence directly downstream of the actual tar-
get sequence) in the repair template. This should abolish its
adverse Cas9-mediated cutting before, during or after re-
combination, and instead restrict Cas9 cleavage to the en-
dogenous locus. Accordingly, we generated an improved re-
pair template in which we point-mutated the gRNA PAM
from the canonical TGG to a TGC that is not recognized by
Streptococcus pyogenes Cas9 (Supplementary Figure S5A).
Importantly, because the point mutation occurred in a small
bulge of the predicted pre-miR-122 structure, it did not af-
fect miR-122 functionality (Supplementary Figure S5B). In
addition, we replaced the Cas9 cDNA in our original con-
struct (50) with a more potently expressed variant (see Sup-
plementary Methods). These two modifications boosted the
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Figure 2. Design and validation of shmiRHCV318. (A) Sequence and secondary structure of human (hsa-) pre-miR-122 and pre-shmiRHCV318. The
nucleotide positions in the 5′ HCV region where the original HCV-321 shRNA or shmiRHCV318 start binding are indicated (321 or 318, respectively).
(B) Schematic representation of expression plasmids created and used to verify that the integration site chosen within the hcr locus allows for multiplexed
shmiRNA co-expression together with miR-122. The parental plasmid (left) contains 1.2 kb of the hcr locus comprising the miR-122 hairpin driven by a
CMV promoter (CMVp). NheI and BamHI restriction sites were inserted 76 nt upstream of the miR-122 5p arm, to facilitate shmiRNA cloning. These
sites were used to insert the shmiRHCV318 hairpin into the hcr plasmid (center, top). The plasmids containing shmiRhAAT (center, bottom) or both,
shmiRhAAT and shmiRHCV318 hairpins (right) upstream of miR-122 carry two BsmBI restriction sites (purple) for insertion of additional shmiRNA
hairpins. (C) Luciferase reporter assays (n = 3) from HEK293T cells transfected with the shmiRNA expression plasmids from panel B at high (20 ng) or
low (2 ng) doses, verifying the possibility to multiplex shmiRNAs within the hcr locus without compromising functionality of miR-122 or co-expressed
shmiRNAs (HCV318 and/or hAAT). psiCheck-2 plasmids with perfect binding sites for miR-122, shmiRHCV318 or shmiRhAAT in the 3′ UTR of Renilla
luciferase were used as reporters. Data are normalized to the corresponding Firefly luciferase signal from each plasmid and to a psiCheck-2 vector without
miRNA/shmiRNA binding sites (empty, set to 1.0). Statistical analysis was a one-way ANOVA with Bonferroni’s multiple comparison post-test in which
each reporter was compared to the empty reporter (stars), or in which the expression plasmids were compared amongst each other (indicated with the
capped lines). RLU, relative light units; ***, P < 0.001; n.s., not significant. Error bars are S.D.
Cas9 cDNA), respectively, or by roughly 10-fold altogether
(Supplementary Figure S5C). Notably, the resulting 33%
clones that were positive for homologous integration using
the improved CRISPR strategy now approached the results
obtained with our second-best TALEN pair T1 (43.8%, Fig-
ure 3B and C).
To remove the floxed NeoR cassette from positive clones,
selected candidates were treated with an AAV vector ex-
pressing Cre recombinase under the strong CAG (chicken
beta-actin) promoter (Figure 3D). Successful excision was
then confirmed by PCR-based detection of resulting 0.7 kb
minicircles (Figure 3E top). From positive pools of cells,
individual cellular clones were expanded further and re-
analyzed using PCR primers that spanned the entire in-
tegration site (red arrows in Figure 3D). As exemplified
for clone T2 31 in Figure 3E (bottom), this procedure was
highly efficient, resulting in elimination of the NeoR cassette
in all of the tested AAV/Cre-treated progeny clones (10 out
of 10, 100%). As expected, this restored G418 sensitivity of
these cells, further evidencing complete removal of the se-
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Figure 3. Integration of shmiRHCV318 into the hcr locus in Huh7 liver cells. (A) Schematic depiction of the strategy pursued to achieve this integration,
including primer pairs used to detect integration or excision events, respectively. HA, homology arm; NeoR, neomycin resistance cassette; HDR, homology-
directed repair; miR-122p, miR-122 promoter. (B) PCR to detect random integration (RI, top) or homologous integration (HI, bottom) after TALEN-
mediated miR-122 editing. In the top panel, black arrow heads indicate clones that were negative for RI and hence further assessed for potential HI. A
subset of results is shown in the bottom gel, where black arrow heads denote positive clones (no RI, but HI). Green or yellow arrows symbolize primers
used (see panel A). TS, TALEN Seed; T1, TALEN 1; T2, TALEN 2. (C) Summary of observed integration events with the three TALEN pairs. Column
‘RI’ lists clones that were positive for RI and thus excluded from further analysis. Vice versa, column ‘No RI’ shows clones that are negative for RI (marked
with arrow heads in the top gel in panel B) and thus potentially positive for HI. Out of these ‘No RI’ clones, a subset was further analyzed (panel B
bottom); resulting numbers of clones with HI are summarized in column ‘HI’. Column ‘Total HI’ depicts numbers and percentages of clones positive for
HI out of the total number of clones analyzed for each TALEN pair. For the T2 samples, this was estimated to be about 65% since we re-tested 13 of the
19 clones without RI from the original 27 (70.4%) and found 12 to be positive for HI (92.3%). (D) Schematic depiction of the strategy used to eliminate the
NeoR cassette after selection, by treating the engineered cells with a Cre recombinase-expressing AAV vector. Also shown is the resulting 0.7 kb minicircle,
whose successful detection by PCR is exemplified in the gel at the top of panel E. (E) Lanes YFP are negative controls where the cells were treated with
an AAV vector expressing YFP instead of Cre recombinase. The bottom gel shows results from PCR reactions to genotype single clones picked from the
Cre-treated Huh7 T2 31 pool (representative example). Expected bands were: wildtype amplicon (WT) 2.5 kb; integration amplicon without NeoR cassette
(NeoR-) 2.7 kb, and integration amplicon with NeoR cassette (NeoR+) 4.3 kb. Note the 100% efficiency as all 10 clones show the pattern expected for a
heterozygous clone (loss of the 4.3 kb and gain of the 2.7 kb band). The arrows in panel E indicate specific PCR primers as shown in panels A and D. U,
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Sequencing analysis of integration events and nuclease-
induced modifications in the miR-122 locus
To verify proper integration of the shmiRHCV318 hairpin,
PCR products spanning the targeted region were ampli-
fied from genomic DNA from some of the engineered cel-
lular clones and then sequenced. Surprisingly, we observed
a broad spectrum of nuclease-induced modifications within
the edited miR-122 hairpin, as illustrated for seven clones in
Figure 4 (complete sequences are shown in Supplementary
Figure S7). Importantly, successful integration of the exoge-
nous shmiRHCV318 hairpin into at least one miR-122 al-
lele was detected in all clones. The only exception was the
Cas9/gRNA-derived clone U6 6.21 which carried a dele-
tion of 4 nucleotides in the WT allele, and a 195 nucleotide
deletion in the edited allele that spanned the shmiRHCV318
hairpin (but not the NeoR cassette, explaining why this
clone was G418-resistant).
Amongst the six other clones, two (T2 4.37 and U6 20.16)
were homozygous for shmiRHCV318 integration, while the
remaining four were heterozygous. This was concluded from
detection of either one (homozygous) or two (heterozygous)
PCR products after AAV/Cre treatment (see Figure 3E
above for an example for a heterozygous clone), and from
sequencing of at least five independent bacterial colonies af-
ter subcloning of each product. The miR-122 hairpin had
remained fully intact in three of these six clones, including
one of the clones with a homozygous shmiRHCV318 inte-
gration (T2 4.37). The other homozygous clone, U6 20.16,
carried an identical 66 nucleotide insertion right upstream
of the PAM sequence in both alleles. Two of the four het-
erozygous clones (T2 31.3 and U6 6.30) had intact miR-122
alleles, while the other two (TS 30.20 and U6 7.16) showed
modifications ranging from a 1 nucleotide insertion, to a 13
nucleotide deletion. Possible explanations for this spectrum
of on-target mutations are provided in Supplementary Dis-
cussion part A.
Originally, we had intended to derive and characterize a
clone with minimal modification of the hcr locus, i.e. het-
erozygous shmiRHCV318 integration and preserved miR-
122 sequence, as is indeed the case with clones T2 31.3
and U6 6.30. However, as miR-122 is a host factor for
HCV (38), we reasoned that partial miR-122 disruption
might in fact inhibit viral replication synergistically, and
thus decided to also study clones with miR-122 modifica-
tions. Overall, we had to restrict our selection to three dif-
ferent clones in order to maintain feasibility of the compre-
hensive downstream analysis, including HCV infection ex-
periments, miRNA profiling and whole genome sequencing
(see below). We therefore selected the following three repre-
sentative clones for all further studies: (i) T2 31.3 (heterozy-
gous for shmiRHCV318, both miR-122 alleles intact), (ii)
TS 30.20 (heterozygous for shmiRHCV318, minor modi-
fications in both miR-122 alleles) and (iii) U6 20.16 (ho-
mozygous for shmiRHCV318, also homozygous for a 66
nucleotide insertion upstream of miR-122).
Characterization of anti-HCV shmiRNA levels and of the dif-
ferent miR-122 phenotypes
Steady-state levels and functionality of the two hairpins
(shmiRHCV318 and miR-122) were first assessed by quan-
titative real-time PCR (qRT-PCR), Northern blotting and
luciferase reporter assays (Figure 5). All three clones ex-
pressed shmiRHCV318 at different levels as detected by
qRT-PCR that correlated with the degree of miR-122 mu-
tation (compare Figure 4 and Supplementary Figure S7),
from about 200 copies per cell for the fully intact clone T2
31.3, to about 25 for the largely miR-122-mutated clone
U6 20.16 (Figure 5A). These numbers were mirrored by
different relative levels of mature shmiRHCV318 as mea-
sured by Northern blotting (Figure 5B top), and they
moreover corresponded well to the extent of inhibition
of a shmiRHCV318-sensitive luciferase reporter, reaching
around 80% for the best clone T2 31.3 (Figure 5C). A sim-
ilar pattern was noted for endogenous miR-122, which was
most prominently detected in clone T2 31.3 but almost ab-
sent in clone U6 20.16 (Figure 5B bottom). Mature miR-122
steady-state levels were reduced by 2.1- or 4.8-fold (by qRT-
PCR) in clones T2 31.3 and TS 30.20, respectively (Figure
5D), congruent with 2-fold lower levels of precursor miR-
122 in clone T2 31.3 (Supplementary Figure S8). See Sup-
plementary Discussion part B for possible reasons for the
mild reduction in clone T2 31.3 despite the absence of mu-
tations in both miR-122 alleles. Notably, this barely affected
knockdown of a miR-122-sensitive luciferase reporter (Fig-
ure 5E). In contrast, clone U6 20.16 which showed 188-fold
lower miR-122 expression in qRT-PCR (Figure 5D) and no
detectable expression by Northern blotting (Figure 5B bot-
tom) also exhibited no miR-122 reporter inhibition (Figure
5E), characterizing this clone as a complete miR-122 knock-
out.
As a control experiment to verify the liver lineage speci-
ficity of our strategy, we also integrated the shmiRHCV318
hairpin into human HEK293 kidney cells in which the miR-
122 locus is inherently silent. With up to 81% (Supple-
mentary Figure S9A and B), the efficiencies of homolo-
gous integration even surpassed those observed in Huh7
cells (Figure 3C), perhaps related to the higher trans-
fectability of HEK293 cells. Interestingly, we noted a mod-
erate read-through effect from the Rous Sarcoma Virus
(RSV) promoter driving the NeoR cassette that resulted
in shmiRHCV318 and miR-122 expression, as detected
by luciferase reporter assays (Supplementary Figure S9C
and D). Most importantly, however, this effect was elimi-
nated once the NeoR cassette and hence the ectopic pro-
moter were floxed out (compare dark and light blue bars
in Supplementary Figure S9D). Accordingly, the fully engi-
neered HEK293 cells no longer exhibited suppression of the
shmiRHCV318 or miR-122 luciferase reporters, identical
to the parental HEK293 cells and in contrast to the Huh7
clone T2 31.3 that was included as positive control. We thus
conclude that expression of integrated shmiRHCV318 is
strictly dependent on the activity of the endogenous miR-
122 promoter (silent in HEK293, but active in Huh7 cells),
and that, vice versa, integration of the exogenous hairpin
does not trans-activate the silent hcr locus in non-hepatic
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Figure 4. Schematic depiction of the results from sequencing of seven selected Huh7 clones after shmiRHCV318 integration. Shown on top are the different
elements that are found in WT miR-122 alleles or expected after successful integration of the shmiRHCV318 hairpin plus floxed NeoR cassette, respectively.
BS, binding site. Illustrated underneath are the different cellular clones, grouped by homo- versus heterozygous editing, and by no, small or large mutations.
The G > C conversion in clone U6 7.16 was expected from the use of a PAM-mutated repair template. Blue: miR-122; red: CRISPR BS; purple: TALEN
T2 BS; green: shmiRHCV318; grey: loxP site; orange: neomycin resistance cassette. See Supplementary Figure S7 for more details on all sequences.
Comprehensive gene and miRNA expression analysis to verify
the similarity of lead clone T2 31.3 to WT Huh7 cells
To further assess the similarity of the three selected cellular
clones and WT Huh7 cells, gene expression profiling of all
cells was performed at three different passages. Analyses of
significantly differentially expressed genes (DEG) revealed
a minor number of DEG in clones T2 31.3 (24 DEG) and
TS 30.20 (16 DEG) (all genes are listed in the Supplemen-
tary Expression profiles). Conversely, a much larger num-
ber of genes were affected in clone U6 20.16 (1797 DEG).
This is evident from Supplementary Figure S10 that visual-
izes the quantiles of the observed versus the expected statis-
tics. The higher similarity of the two TALEN-derived clones
to WT Huh7 cells, especially of clone T2 31.3, is moreover
illustrated by principal component analysis (PCA) which
showed that clones T2 31.3 and TS 30.20 cluster together
and resemble WT Huh7 cells, but are distinct from clone
U6 20.16 (Figure 6A).
Congruent with this, global miRNA expression profil-
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Figure 5. Characterization of selected shmiRHCV318-engineered Huh7 clones. (A and D) qRT-PCR-based quantification of (A) shmiRHCV318 or (D)
miR-122 expression in the three clones or in HEK293T cells (negative control). Total RNA harvested at three different cell passages (n = 3 each) was used.
Data were normalized (Ct method) to the small nucleolar RNA SNORD25 and to Huh7 WT RNA. Error bars are S.D. To calculate absolute numbers
of shmiRHCV318 copies per cell (c/c) in panel A, a standard curve was prepared using a shmiRHCV318 mimic. One outlier was discarded for clone TS
30.20 with a 90% confidence level applying Dixon’s Q-Test. (B) Northern blot to determine shmiRHCV318 and miR-122 expression in the three selected
clones. tRNAQ1 served as loading control. Numbers underneath the bands represent expression of shmiRHCV318 and miR-122 relative to T2 31.3 and
WT cells, respectively. The miR-122 shift in clone TS 30.20 was expected from the one bp insertion (see Figure 4 and Supplementary Figure S7). (C and
E) Luciferase reporter assays (n = 3 each) to determine functionality of shmiRHCV318 and miR-122 in the engineered selected clones at three different
passages. psiCheck-2 reporters with appropriate binding sites were used (see Figure 2C for more details). Error bars are S.D. Statistical analysis was a
one-way ANOVA with a Bonferroni’s multiple comparison post-test. *P < 0.05; **P < 0.01; ***P < 0.001.
and WT Huh7, as opposed to clone U6 20.16 in which nu-
merous miRNAs were expressed aberrantly (Figure 6B; see
Supplementary Discussion part C for possible reasons). The
largest discrepancies in miRNA expression between this
clone and the parental cells were noted for the two strands
of miR-122 (Figure 6C, arrows), concordant with the qRT-
PCR, Northern blotting, sequencing and functional data
(see above). In clone U6 20.16, miR-122 is strongly down-
regulated (fold-change FC = 0.06), while the least difference
was found in T2 31.3 (FC = 0.48); clone TS 30.20 was in be-
tween (FC = 0.18).
Altogether, these data consistently indicate that
shmiRHCV318 expression per se (even the high levels
in clone T2 31.3), and also the additional mutations of
miR-122 in clone TS 30.20, only mildly affected global
gene and miRNA expression. This is in contrast to the
largely miR-122-mutated clone U6 20.16 in which we
noted 100-fold more dysregulated genes (Supplementary
Expression profiles) and poorer clustering (Figure 6) with
the parental cells.
Next, we performed whole genome sequencing of T2
31.3, which had emerged as our lead clone at this point
based on its superior similarity to WT Huh7 cells. We
mapped the whole genome sequencing reads of T2 31.3
and WT Huh7 cells to a concatenated reference genome
consisting of GRCh37 version hs37d5 and the shmiRNA
contig. This identified 37 read pairs which mapped to
shmiRHCV318 and the expected integration locus on chro-
mosome 18 (Supplementary Figure S11). In addition, all
reads overlapping the shmiRNA contig borders support the
intended integration site. Importantly, we detected no read
pair or read overhang mapping to a different genomic posi-
tion or being unmappable, which would have indicated off-
target integration in the Huh7 genome.
Furthermore, we identified single nucleotide variants and
short indels via Platypus (51), and structural variants via
Manta (52), again using GRCh37 version hs37d5 as refer-
ence genome. Only the variants that passed all internal fil-
ters within Platypus and Manta were then used in compar-
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Figure 6. Transcriptome profiles of shmiRHCV318-engineered Huh7 clones. (A and B) Principal component analysis (PCA) performed after (A) gene
expression profiling and (B) miRNA expression profiling of the shmiRHCV318-engineered Huh7 clones. (C) Heat map depicting the most differentially
expressed miRNAs in the three selected shmiRHCV318-engineered Huh7 clones and WT Huh7. Clustering of differentially expressed miRNAs was based
on empirical Bayes analysis (n = 70, false discovery rate < 0.05). The greatest difference is seen for miR-122-5p (red arrow), which is highly expressed in
Huh7 and T2 31.3, but not in TS 30.20 and U6 20.16 cells (the latter showed the lowest expression). Similar differences can be observed for miR-122-3p
(green arrow).
plementary Table S2 shows that in all categories, parental
Huh7 cells had even more private genetic variants than
clone T2 31.3. This suggests that the private variants in
T2 31.3 accumulated during Huh7 clonal derivation rather
than representing specific nuclease-induced variations.
As a whole, these complementary analyses suggested the
presence of a single shmiRHCV318 integration within an
intact miR-122 locus at the expected position in clone T2
31.3. This independently verifies our sequencing data in
Figure 4 and Supplementary Figure S7, and illustrates the
possibility to juxtapose high precision with low genotoxicity
through our nuclease-mediated miRNA engineering strat-
egy.
Validation of efficient and specific impairment of HCV repli-
cation in engineered Huh7 cells
Finally, we challenged all three cell clones with HCV to
study whether their genetic engineering had induced the ex-
pected resistance against HCV. Fourty-eight and 72 h after
electroporation of a subgenomic HCV replicon encoding a
luciferase reporter (surrogate marker for HCV replication
(53)), we noted about 10- (T2 31.3) to 100-fold (TS 30.20)
reduced viral replication in all clones as compared to WT
Huh7 (Figure 7A and Supplementary Figure S12A). HCV
inhibition was likewise pronounced when we electroporated
a full-length reporter virus genome encoding luciferase and
able to form infectious HCV particles (54) (Figure 7B). In
fact, remaining luciferase levels were indistinguishable from
mock-electroporated cells (dashed line in Figure 7B) or a
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Figure 7. Demonstration of the HCV resistance of shmiRHCV318-engineered Huh7 cells. (A–D, F) Luciferase reporter assays (n = 3 each) to measure
inhibition of HCV replication and anti-viral specificity. Huh7 cells were (A, B, D, F) electroporated or (C) infected with a (A, F) subgenomic HCV replicon,
(B, C) a full-length reporter HCV, or (D) a Dengue virus (DV) replicon. All co-encoded luciferase reporters. Dashed lines indicate background levels of the
assays obtained with mock electroporations/infections. (E) Scheme illustrating the mode of action of the shmiRHCV318 antisense strand-specific tough
decoy (TuD), i.e. stable sequestration of this strand by two complementary sequences within the TuD hairpin. (F) Huh7 WT or T2 31.3 cells were transduced
with AAV-DJ encoding a shmiRHCV318 antisense strand-specific TuD at 4 × 104 particles per cell and 1.5 days later electroporated with a subgenomic
HCV replicon. At 72 h post-electroporation, TuD expression had partially rescued the shmiRHCV318-mediated inhibition of HCV replication, resulting
in HCV replication levels that are not significantly different from those in Huh7 WT cells. Samples were harvested at the indicated time points post-
electroporation/-infection, and all data were normalized to the 4 h time point. Error bars are S.D. FLU, Firefly luciferase units; RLU, Renilla luciferase
units. Statistical analysis was a two-way ANOVA with a Bonferroni’s multiple comparison post-test in which every engineered Huh7 clone was compared







niversitatsbibliothek Augsburg user on 07 Septem
ber 2020
PAGE 13 OF 17 Nucleic Acids Research, 2017, Vol. 45, No. 1 e3
tary Figure S12B). Identical findings were made after infec-
tion with purified full-length reporter HCV, which was also
completely blocked in our engineered cells (Figure 7C). Cu-
riously, a Dengue virus (DV) subgenomic replicon used as
control also amplified inefficiently in the TS 30.20 cells, al-
beit it still expressed above the background levels observed
in the mock control (Figure 7D) or expected with fully
replication-deficient DV (55). This indicates that this clone,
which also showed the highest inhibition of the HCV subge-
nomic replicon (Figure 7A), has a defect that broadly im-
pairs replication of flaviviruses. Importantly, the same DV
control behaved normally in clone T2 31.3 and replicated
even slightly better in clone U6 20.16, verifying that the
HCV inhibition observed in these two clones is truly specific
and mediated by the integrated anti-HCV hairpin. This was
further validated through sequestration of the anti-HCV
shmiRHCV318 in clone T2 31.3 with a ‘tough decoy’ in-
hibitor (56), which rescued the inhibition of HCV replica-
tion (Figure 7E and F and Supplementary Figure S13).
DISCUSSION
Here, we demonstrated the feasibility to usurp an endoge-
nous miRNA locus for stable, precise and potent expression
of an exogenous promoterless RNAi hairpin, using nucle-
ases for its site-specific integration. Our lead cellular clone,
T2 31.3, (i) carries a single targeted shmiRHCV318 inte-
gration, (ii) shows neither mutations in the miR-122 alleles
nor substantial changes in gene or miRNA expression (in-
cluding miR-122), (iii) stably expresses shmiRHCV318 for
at least 20 passages (data not shown) and (iv) specifically
and robustly inhibits HCV, together illustrating the great
potential of our new RNAi expression strategy.
Compared to conventional stable transfection or trans-
duction of RNAi cassettes, our unique approach essentially
differs in that it obviates the need for ectopic regulatory el-
ements for RNAi hairpin transcription, especially vector-
borne RNA polymerase II or III promoters. This is highly
advantageous considering that exogenous promoters can
dysregulate cellular genes via cis- or trans-activation, com-
pete for transcription factors, get silenced over time and/or
vary in strength between different cell types (35). A recent
example strikingly illustrating these concerns are findings
in mice that AAV vector integration into the Rian locus
can cause hepatocellular carcinoma (HCC), depending on
vector dose and promoter/enhancer elements (31). Accord-
ingly, HCC incidences reached over 70% when the transgene
was expressed from a chicken beta-actin or a thyroxine-
binding globuline promoter, but 0% with a human alpha-1-
antitrypsin promoter (the same used in clinical AAV trials
(57)). For reasons unknown, the first two promoters but not
the third had induced an upregulation of various small non-
coding RNAs including miR-543 as well as of the Rtl1 gene
(associated with HCC (58)). Importantly, these adverse lo-
calized transcriptional perturbations were not due to the in-
tegration per se since all three vector variants were found
in the Rian locus. Similarly, another study provided evi-
dence that integration of the WT AAV2 3′ inverted terminal
repeat (ITR), believed to have intrinsic enhancer activity,
might be associated with HCC in humans (59). It must be
noted that to date, over 100 clinical trials with AAV vectors
yielded no evidence that this putative tumorigenic prop-
erty is conserved in recombinant ITRs (30,60). Nonetheless,
these latest studies highlight dangers and malignancy risks
that can be associated with ectopic DNA cassettes compris-
ing strong promoters/enhancers and capable of chromo-
somal integration. Our new strategy, where the shmiRNA
lacks its own promoter and is placed under an endogenous
miRNA promoter, helps to alleviate such concerns about cis
or trans perturbation of cellular gene expression, and con-
comitantly promises persistent and cell-specific expression
at physiological levels (depending on the selected miRNA).
With these features, our work complements and expands
on recent efforts to integrate exogenous promoterless cD-
NAs into tissue-specific genes that likewise used homolo-
gous recombination and followed the same rationale. In one
example, the Porteus lab integrated fluorescent reporters
under the - or  -globin promoters in human K562 cells
(61), to screen small compounds for effects on transcription
of the endogenous -/ -globin genes. A second example
comes from the Kay lab who integrated the human factor
IX cDNA into the abundantly expressed albumin locus in
mouse livers, using AAV8 vectors for cDNA delivery (33).
Another study also used AAV vectors and harnessed the
same locus, but integrated other (partial) therapeutic cD-
NAs (62). Moreover, in this work, the efficiency of cDNA
integration was boosted by co-expressing Zinc-finger nucle-
ases (ZFNs) against the albumin locus from AAV vectors.
Finally noteworthy are two studies that generated trans-
genic animals via CRISPR-mediated integration of pro-
moterless ectopic sequences into cellular genes. In one, the
human albumin cDNA was inserted into the albumin locus
in swine zygotes, creating transgenic pigs secreting human
albumin in their blood (63). In the other study, transgenic
mice were created by inserting an artificial miRNA into an
intron of the eEF-2 gene, via microinjection of mouse em-
bryos and subsequent PCR-based selection of positive off-
spring (34).
Our own work adds a unique and versatile concept to this
rapidly growing list of strategies that harness endogenous
elements to control exogenous sequences, by exemplifying
the possibility to engineer and repurpose a human miRNA
locus for shmiRNA expression. Like some of the aforemen-
tioned studies, we employed TALEN and CRISPR nucle-
ases to induce double-stranded DNA breaks and thus boost
the efficiency of homology-directed repair. This benefit of
including nucleases was also highlighted by Sharma et al.
who failed to obtain detectable factor IX levels in mice when
trying to integrate the cDNA in the absence of co-delivered
ZFNs (62). Further informative is that Barzel et al. achieved
only 0.5% gene editing in their nuclease-free in vivo targeting
approach (33). Concurrently, the Zhang lab reported over
40% gene editing with AAV/CRISPR vectors in mouse liv-
ers (64), the same organ targeted by Sharma or Barzel et al.
(33,62). Importantly, this high number only reflects gene
cleavage and faulty repair, leaving open what the frequen-
cies of targeted integration of foreign DNA will be in an in
vivo setting.
Generally, one may conclude that a common asset of
promoterless cDNA or RNAi hairpin integration strategies
is a gain in specificity and safety, compared to promiscu-
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note that our use of current nuclease generations resulted
in sporadic insertions or deletions within the targeted re-
gion. Moreover, we found a slight, 2-fold reduction of ma-
ture miR-122 in our lead clone T2 31.3 despite the absence
of mutations in both miR-122 alleles (see Supplementary
Discussion parts A and B for likely explanations). Together,
this illustrates the spectrum of possible on-target modifi-
cations that can be found and that should be considered
in forthcoming iterations of our new approach. Whether
or not such extra alterations can be tolerated will depend
on the exact target and application. In the case of miR-
122 and HCV, they might in fact be beneficial in view of
this miRNA’s critical role as viral dependency factor and of
in vivo data that miR-122 inhibition suppresses viremia in
HCV-infected chimpanzees and patients (65–67). Congru-
ent with this, clone U6 20.16 with a large mutation in both
miR-122 alleles even outperformed our lead clone T2 31.3 at
inhibiting subgenomic HCV replicons. However, U6 20.16
also differed in global gene and miRNA expression profiles
(see Supplementary Discussion part C for possible reasons),
hampering direct comparison. One should moreover con-
sider that miR-122 plays various essential roles in the liver
and acts as tumor suppressor (68,69), suggesting the impor-
tance of keeping at least one allele intact when engineering
this locus. As noted, this was indeed the case in clone T2
31.3 and in three others: T2 4.37 and U6 6.30 (both miR-
122 alleles intact), and U6 7.16 (one allele intact); i.e. 4 out
of 7 (57%).
Next to on-target effects, one must consider possible ad-
verse off-target modifications, although they seem rare in
our lead clone T2 31.3 within the detection limits of our
assays. Fortunately, nuclease specificity is an area of highly
active inquiry, and there are already numerous encourag-
ing options to minimize off-targeting. Most notable are
the latest generations of CRISPR/Cas9 systems with im-
proved specificity and safety, including truncated gRNAs,
double-nicking approaches, Cas9 orthologs, high-fidelity
Cas9 mutants, the Cpf1 nuclease or split Cas9 variants (70–
80). Looming efforts to enhance CRISPR specificity will
concomitantly benefit from the expanding repertoire of ex-
perimental options to detect these adverse events, such as
ChiP-Seq, Digenome-Seq or GUIDE-Seq (81–86). While
our present focus was to provide proof-of-concept for our
novel strategy including a first characterization of possible
outcomes, we readily anticipate that future iterations will
greatly profit from these tools and hence see an increase in
specificity and thus safety.
These improved CRISPR systems and their compatibility
with gene delivery vehicles (87,88) also imply a broad appli-
cability of our new RNAi expression strategy beyond our
feasibility study in cultured liver cells. One intriguing use
could be ex vivo engineering of induced pluripotent stem
cells before differentiation into liver cells, or direct modi-
fication of primary human hepatocytes. In both cases, in-
tegration of RNAi hairpins could genetically ‘immunize’
these cells against infection with hepatitis viruses prior to
transplantation into a patient with hepatitis. Likewise, en-
gineering an anti-HIV RNAi hairpin into a miRNA locus
in hematopoietic progenitor cells could yield HIV-resistant
cells for autologous transplantation. This would be sim-
ilar to, but probably genetically safer than, clinical trials
in which such hairpins were stably delivered with lentivi-
ral vectors under exogenous promoters (89). Interestingly,
miR-122 is induced during HIV infection (90), implying
that our miR-122-specific tools and strategies could be di-
rectly applied. Moreover, notable is our evidence that the
miR-122 locus (and likely others as well) tolerates at least
two different additional hairpins, which could be useful
to inhibit highly mutagenic viruses such as HCV or HIV
with combinatorial RNAi (91,92). Such attempts will profit
from the vast experience in multiplexing of RNA hairpins
gained in other contexts, including long hairpin RNA pre-
cursors, engineered miRNA polycistrons, extended short
hairpin RNAs or clusters of TuD inhibitors, to name a few
(92–96). A third attractive example for clinical applications
are human cancers which are frequently characterized by
dysregulation of cellular miRNAs (97), suggesting the pos-
sibility to exploit viral CRISPR vectors (50,64,87,88) to in-
tegrate cytotoxic RNAi hairpins into miRNA genes that are
aberrantly up-regulated.
We moreover see great potential of our new approach
for generation of transgenic knockdown animals that sta-
bly express RNAi hairpins, to study gene function in normal
physiology or disease. For these models to be stringent, it is
essential to avoid local effects of integration sites, multiple
single or tandem insertions, or transgene silencing. All these
side effects are typical for conventional transgenesis tech-
nologies, but may be overcome by repurposing cellular pro-
moters for expression of minimal RNAi hairpins. One study
exploited a ubiquitously expressed mouse gene for this pur-
pose (34), but our own strategy that uses a tissue-specific
miRNA locus may be even more beneficial as it combines
robust expression with high lineage specificity. Finally, our
approach to link exogenous to endogenous RNAi triggers,
or, generally, to precisely engineer and harness miRNA loci
for expression of detectable foreign RNA sequences, should
prove valuable for investigations into fundamental cellular
RNAi and genome biology. This could include a direct re-
placement of a target miRNA with another artificial or nat-
ural miRNA, to study effects on physiology, differentiation
or other basic cellular parameters.
We acknowledge that all these future applications, espe-
cially direct in vivo use and other advances toward clinical
translation, require improvements in efficiency and accu-
racy of nuclease-mediated DNA modification. Ideally, these
will alleviate the necessity for clonal selection, which re-
sults from the possibility of undesirable on- and off-target
modifications that is inherent to all current nucleases. We
are aware of these restrictions but reiterate that these are
not intrinsic to our original strategy, and that some con-
cerns about efficiency and specificity will be resolved with
newer generations of nucleases and delivery systems. Partic-
ularly encouraging is the aforementioned report of greater
than 40% targeted gene editing in adult mouse livers, using
moderate doses of an AAV8 vector expressing Cas9 from
S. aureus and delivered via peripheral infusion (64). Similar
optimism is raised by the successful AAV/ZFN-mediated
in vivo integration of promoterless cDNA in mouse livers
(62). We further note an intriguing study showing cell-to-
cell transfer of small RNAs in livers of mice (98), imply-
ing that therapeutic benefit may be achieved from editing
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gans). It may also be rewarding to replace Cre recombinase
with alternatives posing a lower inherent risk of chromo-
somal translocation (albeit not observed in our study), e.g.
hyperactive piggyBac transposase delivered as protein (99).
Finally promising is that homology-directed repair can be
promoted in mammalian cells and mice by suppressing key
factors in the non-homologous end joining pathway, such
as DNA ligase IV, which expands the options to enhance
frequencies of targeted modification of miRNA loci (100–
102). In light of these and other advances, and of the ex-
treme pace with which the entire genome engineering field
is currently progressing, we are optimistic that the way will
soon be paved for a wealth of exciting ex or in vivo applica-
tions of our new concept for safe and accurate expression
of exogenous RNAi hairpins.
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